Last reviewed · How we verify
NCT06779981
A Prospective Epidemiological Study Evaluating Occurrences of Influenza-like Illness
trial testing Nasopharyngeal swabs in Influenza in 119 participants. Completed in 19 June 2025.
19 June 2025
Quick facts
| Lead sponsor | Osivax |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 119 |
| Start date | 13 December 2024 |
| Primary completion | 19 June 2025 |
| Estimated completion | 19 June 2025 |
| Sites | 1 location across Belgium |
Drugs / interventions tested
- Nasopharyngeal swabs — full drug profile →
Conditions studied
- Influenza — all drugs for Influenza →
Sponsor
Osivax — full company profile →
Who can join
Adults 20 to 64, any sex, with Influenza. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This prospective epidemiological cohort study is being conducted in order to generate epidemiological data in support of Osivax's clinical development of a broad-spectrum influenza vaccine based upon the internal influenza nucleoprotein (NP), i.e., OVX836.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06779981
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Nasopharyngeal swabs
Trials testing the same drug.
- NCT04584541 — SarS-Cov-2 Viral Infection (COVID-19) in Patients With Chronic Inflammatory Rheumatism · NA · terminated
- NCT04369066 — COVID-19 Study of the Serological Response Against the Severe Acute Respiratory Syndrome (SARS) Coronavirus 2 (CoV-2) Vi · NA · completed
Other recruiting trials for Influenza
Currently open trials in the same condition.
- NCT07215858 — BPL-1357 Against H1N1 Influenza Virus Challenge · Phase 2 · recruiting
- NCT07496450 — A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy Adults · Phase 3 · recruiting
- NCT07302256 — A Clinical Trial of Influenza Virus Split Vaccine for Individuals Aged 60 Years and Above · Phase 1 · recruiting
- NCT07431840 — Immune Defense Protein Impact On Respiratory Immune Outcomes · NA · recruiting
- NCT07485855 — Influenza Vaccination Strategy for Patients With Hematologic Malignancy · Phase 3 · recruiting
Other Osivax trials
Trials by the same sponsor.
- NCT05569239 — Efficacy, Immunogenicity and Safety of OVX836 Influenza Vaccine 480μg · Phase 2 · active not recruiting
- NCT06582277 — Safety and Immunogenicity of Two Dose Levels of OVX836 Influenza Vaccine as a Booster on Participants Previously Adminis · Phase 2 · completed
- NCT06128382 — First-in-human Study to Evaluate the Safety and Immunogenicity of Three Dose Levels of the OVX033 Coronavirus Vaccine Ca · Phase 1 · completed
- NCT05734040 — Immunogenicity and Safety of the Concomitant Administration of OVX836 Influenza Vaccine, Quadrivalent Inactivated Influe · Phase 2 · completed
- NCT05284799 — Immunogenicity and Safety of the Concomitant Administration of OVX836 and Quadrivalent Influenza Vaccine in Healthy Volu · Phase 2 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06779981 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Osivax
- Last refreshed: 25 June 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06779981.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing